Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alan M Garber is Director at Vertex Pharmaceuticals. OQRO lists 5 transactions filed with the SEC under this name, the latest on Oct 19, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
Alan M Garber has no open-market purchase on record since 2016. Sales in 8 of the 11 years since 2016.
Alan M Garber reported 0 open-market purchases and 14 sales since 2016; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $461K1×1 trade |
| 2023 | — | $700K1×1 trade |
| 2022 | — | $447K1×1 trade |
| 2021 | — | $944K1×1 trade |
| 2020 | — | $2.71M3×3 trades |
| 2019 | — | $978K3×3 trades |
| 2018 | — | $758K3×3 trades |
| 2016 | — | $132K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Vertex PharmaceuticalsVRTX
5 disclosures · Apr 2026 – Oct 2026
Oct 15, 202629.27disclosed Oct 19
DetailsOfficial recordJul 15, 202631.56disclosed Jul 17
DetailsOfficial recordMay 1, 2026472disclosed May 5
DetailsOfficial recordMay 1, 20261,433disclosed May 5
DetailsOfficial recordApr 15, 202633.9disclosed Apr 17
DetailsOfficial recordAs of the latest filing on , Alan M Garber reported holding 7,344 shares of Vertex Pharmaceuticals (VRTX), worth about $3.82M at the last close of $521 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals VRTX | 7,344 | 7,344 direct | $521 | $3.82M | May 1, 2026 |
Is this Alan M Garber’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Alan M Garber reported 0 open-market purchases and 14 sales here, 2016 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated May 1, 2026, Alan M Garber reported holding 7,344 shares of Vertex Pharmaceuticals (VRTX). At the last close of $521 on Nov 19, 2026, that is about $3.82M. This is the stake disclosed in filings, not a net worth.
No public filing gives Alan M Garber's net worth. What SEC Form 4 shows is the stock stake: 7,344 shares of Vertex Pharmaceuticals (VRTX), about $3.82M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Alan M Garber has no open-market purchase on record since 2016. Sales in 8 of the 11 years since 2016.
In SEC filings since 2016: no open-market purchase is on record; the latest open-market sale is from 2024.
Exelixis (EXEL), from 2016 to 2024: 0 purchases and 14 sales.